Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
City of Hope Medical Center
With
National Cancer Institute (NCI)
PRIMARY OBJECTIVE:
I. To assess imaging performance of the fluorine F 18 piflufolastat (\[18F\]-DCFPyL) PET-CT subsystem on the X1 RMRS to detect lesions (primary and metastatic) in patients with prostate cancer.
SECONDARY OBJECTIVE:
I. To determine the feasibility of generating a biology-guided radiotherapy (BgRT) plan using X1 RMRS-acquired \[18F\]-DCFPyL PET data derived from the imaging-only session at the studied dose level.
OUTLINE:
Patients receive \[18F\]-DCFPyL intravenously (IV) and undergo \[18F\]-DCFPyL PET-CT over 30 minutes per standard of care (SOC). Patients with PET avid lesions then undergo a X1 RMRS PET-CT imaging-only session within 120 minutes of injection over 20-35 minutes.
After completion of study, patients are followed up within 72 hours.
Age
21–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Documented informed consent of the participant and/or legally authorized representative
Age \>= 21 years
Patients undergoing SOC \[18F\]-DCFPyL PET-CT
Patients should be scheduled for \[18F\]-DCFPyL PET-CT prior to study entry
You may not be if
Known psychiatric or substance abuse disorder that would interfere with conduct of the study
Patient weight exceeding the weight limit (450 pounds) outlined per X1 RMRS specifications sheet
Clareo Health | RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer
